Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
(OP:
MDXXF
)
0.2313
-0.0053 (-2.24%)
Streaming Delayed Price
Updated: 12:28 PM EST, Nov 19, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
16,800
Open
0.2270
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.2366
Today's Range
0.2270 - 0.2366
52wk Range
0.0476 - 0.3500
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
PharmAla Biotech To Supply LaNeo MDMA For Mt. Sinai Clinical Trial
October 21, 2024
PharmAla Biotech will supply GMP LaNeo MDMA to Mt. Sinai Health System for clinical research, advancing therapy for neurological disorders.
Via
Benzinga
PharmAla to supply Mt. Sinai Hospital with LaNeo MDMA
October 21, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Performance
YTD
+21.10%
+21.10%
1 Month
+72.35%
+72.35%
3 Month
+293.37%
+293.37%
6 Month
+44.56%
+44.56%
1 Year
+21.10%
+21.10%
More News
Read More
PharmAla Biotech To Supply University Of Texas, San Antonio For Clinical Trial
October 08, 2024
Via
Benzinga
PharmAla Biotech To Supply MDMA For Harvard's Maclean Hospital Clinical Trial
October 02, 2024
Via
Benzinga
PharmAla Biotech Partners With Johns Hopkins University For MDMA Clinical Trials, Terminates Red Light Holland Contract
September 11, 2024
Via
Benzinga
PharmAla Launches MDMA Clinical Trial Tool for Researchers
August 22, 2024
From
PharmAla Biotech
Via
GlobeNewswire
PharmAla Comments on USFDA Decision regarding MDMA-Assisted Therapy and Announces Patent Granting for ALA-002
August 09, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Canadian Biotech Duo Hits Psilocybin Extraction Milestone For API Development At Scale
May 29, 2024
Via
Benzinga
Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More
April 17, 2024
Via
Benzinga
Cortexa Commences Manufacturing GMP LaNeo™ MDMA in Australia
April 05, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Psychedelics Headlines: A Form Of Life, Treating Chronic Pain, Microdosing And More
March 30, 2024
Via
Benzinga
Psyched: 5-MeO-DMT For Depression, Utah Hospitals Providing Therapy, Elon Musk And Meta's Influence
March 29, 2024
Via
Benzinga
PharmAla's Novel MDMA Mixture Awarded US Patent, Enabling IP Protection And Further Development
March 27, 2024
Via
Benzinga
Topics
Intellectual Property
Exposures
Intellectual Property
Patent Allowance Granted for ALA-002 Composition by US Patent and Trademark Office
March 27, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Two Top Biotechs Forge MDMA Supply Deals For Clinical Research
March 26, 2024
Via
Benzinga
Patent Allowance Granted for P-1 Molecule by US Patent and Trademark Office
March 20, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Cortexa Leads the World in First Supply of Psilocybin Under the TGA’s Authorized Prescriber Scheme
March 18, 2024
From
PharmAla Biotech
Via
GlobeNewswire
Truffles To Market: Red Light Holland Wants To Develop Psilocybin API At Scale
March 11, 2024
Via
Benzinga
Psychedelics Headlines: Trauma-Informed Care, Valentine's Day & MDMA, Academics On Drugs And More
February 15, 2024
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.
